Ellagic acid and Sennoside B inhibit osteosarcoma cell migration, invasion and growth by repressing the expression of c-Jun

Wei Xu; Jinjin Xu; Ting Wang; Weibo Liu; Haifeng Wei; Xinghai Yang; Wangjun Yan; Wang Zhou; Jianru Xiao

doi:10.3892/ol.2018.8712

Ellagic acid and Sennoside B inhibit osteosarcoma cell migration, invasion and growth by repressing the expression of c-Jun

Oncol Lett. 2018 Jul;16(1):898-904. doi: 10.3892/ol.2018.8712. Epub 2018 May 16.

Authors

Wei Xu¹, Jinjin Xu², Ting Wang¹, Weibo Liu¹, Haifeng Wei¹, Xinghai Yang¹, Wangjun Yan¹, Wang Zhou¹, Jianru Xiao¹

Affiliations

¹ Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
² Shanghai Key Laboratory of Regulatory Biology, Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), Institute of Biomedical Sciences, East China Normal University, Shanghai 200241, P.R. China.

Abstract

Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma that is the most frequently diagnosed primary malignant bone tumor. Today, chemoprevention is regarded as a promising and realistic approach in the prevention of human cancer. Previous studies have suggested ellagic acid (EA) and Sennoside B have potential in this regard. The aim of the present study was to elucidate the anti-osteosarcoma effects of EA and Sennoside B by using Saos-2 and MG63 osteosarcoma cells. It was identified that EA or Sennoside B treatment could inhibit the growth, migration and invasion of the cells, and induce G₁ cell cycle arrest by repressing the transcription of c-Jun. These results may provide a cellular basis for the application of EA or Sennoside B in the treatment of patients with osteosarcoma.

Keywords: c-Jun; ellagic acid; growth; migration; osteosarcoma; sennoside B.